News / US / cnbc
Healthcare Stocks Stumble as Novartis Trial Fails; Boeing Deliveries Lag
Health Technology · Pharmaceuticals: Major · cnbc · 2026-09-08
@CL.1, US10Y, .SPX, .IXIC, NVS, .DJI, AMGN, BA, NVS, LLY, XBI, @LCO26X, ABBV, GILD, NVDA, CHWY, SIG
Novartis shares dropped following a failed cardiovascular trial, weighing on the broader biotech sector, while Boeing reported a monthly decline in aircraft deliveries.
What Happened
Biotech Sector Volatility: Healthcare stocks faced significant pressure after Novartis reported that a Phase 3 trial for a cholesterol-lowering medication failed to improve cardiovascular outcomes. The negative results caused an 11% decline in Novartis shares and dragged down other industry players like Amgen, which is developing a similar treatment.
Eli Lilly Resilience: Despite the broader sector downturn, Eli Lilly shares showed relative stability, falling only 2%. Analysts at JPMorgan reiterated their positive outlook on the company, highlighting its strong pipeline of obesity drugs and potential for revenue growth in the international market.
Boeing Delivery Performance: Boeing reported 51 aircraft deliveries in August, a decrease from both the previous month and the same period in 2025. While the 737 Max program showed slight sequential improvement, the company remains behind its annual delivery targets, with investors watching for updates from management regarding production rates.
Market and Macro Outlook: Broader markets were pressured by rising oil prices and bond yields, with investors awaiting upcoming CPI and PPI data to gauge the Federal Reserve's next policy move. The interplay between fuel costs and aerospace economics remains a key concern for Boeing shareholders, even as the company maintains a backlog without recent cancellations.